teclistamab
genmab,janssen
['multiple myeloma', 'teclistamab', 'majestec-1']
a weekly dose of teclistamab resulted in high response rates among adults with relapsed or refractory multiple myeloma, based on data from the majestec-1 study. #asco22 
MDedge Hematology & Oncology provides the most important and up to date information and news for oncologists. Now part of the Medscape Professional Network.